Biological and therapeutic implications of the BRAF pathway in histiocytic disorders.

Abstract excerpt

Langerhans cell histiocytosis (LCH) has historically evolved in its classification from a primary immune dysregulatory disorder to what current evidence supports as a dendritic cell neoplasm with an immune-inflammatory component. A key part of the classification of LCH as a neoplasm has been the identification of BRAF V600E mutations in 35% to 60% of cases. Tumor protein p53 (TP53) and RAS mutations have also...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Erdheim-Chester Disease
• Share to Extracellular Signal-Regulated MAP Kinases